CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics
December 8th, 2023
This protocol describes a CRISPR-Cas-mediated, multianalyte synthetic urine biomarker test that enables point-of-care cancer diagnostics through the ex vivo analysis of tumor-associated protease activities.
The Heart Lab is engineering molecular and cellular tools to precisely track and control disease biology. We use special information about diseased tissues to inform the design of responsive detection, imaging, and treatment tools for heterogeneous disorders. Biofluids present a convenient opportunity for disease detection and assessment, but these are often limited by low quantities of relevant analytes.
As a result, much of the field is pursuing strategies to amplify disease associated signals to improve the sensitivity of diagnostic tests, like BCR and surface plasma on resonance. Rather than relying on endogenous disease biomarkers in circulation, our approach uses synthetic biomarkers to report disease activity when released from injected nanosensors. Our synthetic biomarkers are chemically stabilized DNA barcodes, which allow for multiple disease microenvironment signals to be detected at once, and identified using the corresponding barcode.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol describes a CRISPR-Cas-mediated, multianalyte synthetic urine biomarker test that enables point-of-care cancer diagnostics through the ex vivo analysis of tumor-associated protease activities. The Heart Lab is engineering molecular and cellular tools to precisely track and control disease biology.
Key Study Components
Area of Science
- Neuroscience
- Biotechnology
- Diagnostics
Background
- Biofluids are convenient for disease detection but often limited by low quantities of relevant analytes.
- Strategies are being developed to amplify disease-associated signals to improve diagnostic test sensitivity.
- Current methods rely on synthetic biomarkers rather than endogenous disease biomarkers.
- Injected nanosensors release synthetic biomarkers to report disease activity.
Purpose of Study
- To develop a synthetic urine biomarker test for cancer diagnostics.
- To enhance the sensitivity of disease detection through engineered molecular tools.
- To utilize stabilized DNA barcodes for detecting multiple disease signals simultaneously.
Methods Used
- CRISPR-Cas technology for biomarker testing.
- Ex vivo analysis of tumor-associated protease activities.
- Design of responsive detection tools based on disease microenvironments.
- Use of chemically stabilized DNA barcodes for signal detection.
Main Results
- Successful development of a multianalyte synthetic urine biomarker test.
- Improved sensitivity in detecting disease-associated signals.
- Demonstration of the effectiveness of synthetic biomarkers in reporting disease activity.
- Potential for point-of-care diagnostics in cancer detection.
Conclusions
- The synthetic urine biomarker test represents a significant advancement in cancer diagnostics.
- Engineered molecular tools can enhance disease tracking and treatment.
- This approach may lead to more effective point-of-care diagnostic solutions.
Frequently Asked Questions
Executive Industry Relevance
CRISPR-Cas-mediated multianalyte synthetic urine biomarker testing enables highly sensitive, multiplexed detection of disease-associated proteolytic activity in vivo, supporting precision diagnostics beyond traditional biofluid assays. This approach addresses the challenge of low endogenous analyte abundance by leveraging engineered nanosensors and DNA barcodes for robust, minimally invasive readouts. The platform's adaptability and multiplexing capacity position it as a strategic asset for early discovery, target validation, and translational biomarker development in oncology and other complex disease areas.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of disease-relevant protease activity directly in the tumor microenvironment.
- Supports functional target validation by linking proteolytic signatures to disease incidence and progression.
- Facilitates predictive confidence in target engagement through multiplexed DNA barcode readouts.
Screening & Assay Development
- Provides validated synthetic biomarker systems for downstream assay development and screening workflows.
- Delivers quantitative, multiplexed outputs for robust assay standardization and reproducibility.
- Enables scalable, portable diagnostic platforms suitable for high-throughput compound evaluation.
Translational & Preclinical Research
- Aligns synthetic biomarker signals with disease biology for translational biomarker discovery.
- Supports continuity from preclinical models to clinical biomarker strategies via minimally invasive urine sampling.
- Reduces mechanistic ambiguity by directly linking molecular activity to disease state in vivo.
Pipeline & Workflow Integration
This synthetic biomarker platform integrates from early discovery through preclinical validation, enabling seamless transition from mechanistic studies to translational biomarker development.
- Discovery Biology: Amplifies disease-associated signals for hypothesis testing and pathway clarification.
- Screening: Provides multiplexed, quantitative readouts for assay readiness and reproducibility.
- Analytics: Enables sensitive detection and comparison of multiple proteolytic activities via DNA barcode analysis.
- Translational Research: Bridges preclinical and clinical biomarker strategies through noninvasive urine-based diagnostics.
- Enterprise Reuse: Offers a modifiable, reusable platform adaptable to diverse disease contexts and biomarker panels.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces biological risk in target validation and biomarker discovery.
- Operational Value: Standardizes multiplexed detection workflows and supports scalable, portable diagnostics.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by enabling early, robust disease signal detection.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of biomarker-driven programs.
Implementation Considerations
- Requires expertise in synthetic biology, CRISPR-Cas systems, and bioanalytical assay development.
- Needs access to instrumentation for DNA barcode detection and CRISPR-based signal readout.
- Demands cross-team standardization for nanosensor synthesis and urine collection protocols.
- Adaptable to various preclinical models and disease microenvironments with appropriate validation.
- Practical limitations include optimization of reporter pharmacokinetics and signal amplification for specific disease contexts.
